Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ellem Läkemedel was a Swedish pharmaceutical company focused on marketed over-the-counter consumer health products rather than a clinical development pipeline. The company was headquartered in Danderyd, Sweden, and was known for products including Bamyl, an analgesic tablet, and AfterBite, a topical product for insect bites. In 2008, Ellem was acquired by Meda, and the business subsequently became part of the Meda corporate structure. Because Meda itself was later acquired by Mylan in 2016, and Mylan subsequently became part of Viatris, Ellem is best understood as a legacy acquired Swedish pharma asset rather than an independent operating biotech company. The available public information does not indicate an active standalone R&D pipeline or platform technology under the Ellem name.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ellem Läkemedel.